The FDA has approved the Lumax 740 implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy devices (CRT-D) from BIOTRONIK.
The Lumax 740 line, which was designed to help physicians monitor and treat arrhythmias and heart failure, features the company’s proprietary SMART Detection technology to reduce the incidence of inappropriate shocks to the heart.
As the press release explains:
Atrial arrhythmias are the main reason for inappropriate shocks. Lumax 740 devices are equipped with a highly sensitive and specific algorithm called SMART Detection®, which automatically extends to redetection to discriminate between true ventricular arrhythmias and supra-ventricular tachycardia. In contrast to competitors, BIOTRONIK’s SMART Detection® continues to fully function even after a first therapy attempt, which allows the device to provide pain-free therapies without compromising specificity. The ability to differentiate atrial from ventricular arrhythmias with high specificity reduces the risk for painful inappropriate shocks.
The Lumax 740 devices also feature the company’s TI technology, which uses thoracic impedance to detect increasing lung fluid levels. The doctor can use data resulting from this measurement to manage the patient’s fluid levels through pharmacotherapy.
The Lumax 740 uses the company’s Home Monitoring system to automatically transmit patient information from the device to the physician on a daily basis. This remote patient management system has been approved by the FDA and has also received CE-approval for early detection of clinically relevant events. At present, the Home Monitoring system is used in more than 5300 clinics located in 56 countries worldwide.
Press release: FDA Approves BIOTRONIK Next Generation ICDs and CRT-Ds…
Product page: Lumax 740…